To evaluate the efficacy of 48-weeks of tenofovir disoproxil fumarate (TDF) therapy on initial treatment and nucleoside analoguese(NAs) -experienced resistant chronic hepatitis B (CHB) patients.

The data of 66 CHB patients included 30 cases of initial treatment and resistant 36 cases with NAs-experienced CHB patients were collected from July 2014 to June 2015. All the patients received TDF 300 mg/d for 48 weeks. Biochemical and virological indexes at baseline, week 4, week 12, week 24, week 36 and week 48 during treatment were collected for evaluation. The differences of the baseline characteristic between initial treatment group and NA-experienced group were evaluated by independent t test; The cumulative incidences of virological response (VR), HBeAg loss and serum alanine aminotransferase (ALT) normalization rate were determined using the Kaplan-Meier method with the log-rank test.

Among the initial treatment patients, the cumulative incidences of VR, HBeAg loss and ALT normalization at weeks 48 were 83.3%, 73.3%, 30.0% respectively. The cumulative incidences of VR, HBeAg loss and ALT normalization in initial treatment patients had no difference with lamivudine/telbivudine resistant mutants patients and entecavir-resistant mutant patients; In contrast, patients previously infected with adefovir-resistant mutant showed lower rates of VR at week 4, week 12, week 24, week 36, week 48 than initial treatment patients, but the difference was not significant. The cumulative incidences of HBeAg loss and ALT normalization between initial treatment patients and adefovir-resistant mutant patients had no significant difference.

TDF is effective for initial treatment and NA-experienced CHB patients.

Hepatitis B; Tenofovir disoproxil fumarate; Nucleoside analogues; Drug resistant